|
[1]
|
Rizvi, S., Khan, S.A., Hallemeier, C.L., et al. (2018) Cholangiocarcinoma—Evolving Concepts and Therapeutic Strate-gies. Nature Reviews. Clinical Oncology, 15, 95-111. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Banales, J.M., Cardinale, V., Carpino, G., et al. (2016) Cholangiocarcinoma: Current Knowledge and Future Perspectives Con-sensus Statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nature Reviews Gas-troenterology & Hepatology, 13, 261-280. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Cholangiocarcinoma Working Group (2020) Italian Clinical Practice Guidelines on Cholangiocarcinoma—Part I: Classification, Diagnosis and Staging. Digestive and Liver Disease: Official Journal of the Italian Society of Gastroenterology and the Italian Associa-tion for the Study of the Liver, 52, 1282-1293. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Banales, J.M., Marin, J.J.G., Lamarca, A., et al. (2020) Cholangio-carcinoma 2020: The Next Horizon in Mechanisms and Management. Nature Reviews. Gastroenterology & Hepatology, 17, 557. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Khan, S.A., Tavolari, S. and Brandi, G. (2019) Cholangiocarci-noma: Epidemiology and Risk Factors. Liver International, 39, 19-31. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Cardinale, V. (2019) Classifications and Misclassification in Cholangiocar-cinoma. Liver International, 39, 260-262. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Kam, A.E., Masood, A. and Shroff, R.T. (2021) Current and Emerging Therapies for Advanced Biliary Tract Cancers. The Lancet. Gastroenterology & Hepatology, 6, 956-969. [Google Scholar] [CrossRef]
|
|
[8]
|
Rawla, P. and Samant, H. (2022) Primary Sclerosing Chol-angitis. StatPearls Publishing, Treasure Island.
|
|
[9]
|
Bowlus, C.L., Lim, J.K. and Lindor, K.D. (2019) AGA Clinical Practice Update on Surveillance for Hepatobiliary Cancers in Patients with Primary Sclerosing Cholangitis: Expert Re-view. Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroentero-logical Association, 17, 2416-2422. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Fouassier, L., Marzioni, M., Afonso, M.B., et al. (2019) Signalling Networks in Cholangiocarcinoma: Molecular Pathogenesis, Targeted Therapies and Drug Resistance. Liver International: Official Journal of the International Association for the Study of the Liver, 39, 43-62. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Bouvard, V., Baan, R., Straif, K., et al. (2009) A Review of Human Carcin-ogens—Part B: Biological Agents. The Lancet. Oncology, 10, 321-322. [Google Scholar] [CrossRef]
|
|
[12]
|
Schwartz, D.A. (1980) Helminths in the Induction of Cancer: Opisthorchis Viverrini, Clonorchis Sinensis and Cholangiocarcinoma. Tropical and Geographical Medicine, 32, 95-100.
|
|
[13]
|
Brindley P.J., Bachini, M., Ilyas, S.I., et al. (2021) Cholangiocarcinoma. Nature Reviews. Disease Primers, 7, 65. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Kim, H.J., Kim, J.S., Suh, S.J., et al. (2015) Cholangiocarcinoma Risk as Long-Term Outcome after Hepatic Resection in the Hepatolithiasis Patients. World Journal of Surgery, 39, 1537-1542. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Barner-Rasmussen, N., Pukkala, E., Hadkhale, K., et al. (2021) Risk Factors, Epidemiology and Prognosis of Cholangiocarcinoma in Finland. United European Gastroenter-ology Journal, 9, 1128-1135. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Clements, O., Eliahoo, J., Kim, J.U., et al. (2020) Risk Factors for Intra-hepatic and Extrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis. Journal of Hepatology, 72, 95-103. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Kubo, S., Shinkawa, H., Asaoka, Y., et al. (2022) Liver Cancer Study Group of Japan Clinical Practice Guidelines for Intrahepatic Cholangiocarcinoma. Liver Cancer, 11, 290-314. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Baison, G.N., Bonds, M.M., Helton, W.S., et al. (2019) Choledochal Cysts: Similarities and Differences between Asian and Western Countries. World Journal of Gastroenterology, 25, 3334-3343. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Petrick, J.L., Yang, B., Altekruse, S.F., et al. (2017) Risk Factors for Intrahepatic and Extrahepatic Cholangiocarcinoma in the United States: A Population-Based Study in Seer-Medicare. PLOS ONE, 12, e0186643. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Jang, M.H., Lee, Y.J. and Kim, H. (2014) Intrahepatic Cholan-giocarcinoma Arising in Caroli’s Disease. Clinical and Molecular Hepatology, 20, 402-405. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Wang, Y., Yuan, Y. and Gu, D. (2022) Hepatitis B and C Virus Infections and the Risk of Biliary Tract Cancers: A Meta-Analysis of Observational Studies. Infectious Agents and Can-cer, 17, 45. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Chang, J.S., Tsai, C.-R. and Chen, L.-T. (2013) Medical Risk Factors Associated with Cholangiocarcinoma in Taiwan: A Population-Based Case-Control Study. PLOS ONE, 8, e69981. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Vij, M., Puri, Y., Rammohan, A., et al. (2022) Patho-logical, Molecular, and Clinical Characteristics of Cholangiocarcinoma: A Comprehensive Review. World Journal of Gastrointestinal Oncology, 14, 607-627. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Cotter, T.G. and Rinella, M. (2020) Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. Gastroenterology, 158, 1851-1864. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Lazarus, J.V., Colombo, M., Cortez-Pinto, H., et al. (2020) NAFLD—Sounding the Alarm on a Silent Epidemic. Nature Reviews. Gastroenterology & Hepatology, 17, 377-379. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Kinoshita, M., Kubo, S., Tanaka, S., et al. (2016) The Association between Non-Alcoholic Steatohepatitis and Intrahepatic Cholangiocarcinoma: A Hospital Based Case-Control Study. Journal of Surgical Oncology, 113, 779-783. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Parsi, M.A. (2013) Obesity and Cholangiocarcinoma. World Journal of Gastroenterology, 19, 457-462. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Menon, S. and Mathew, R. (2019) Association between Metabolic Syndrome and Hepatobiliary Cancers: A Case-Control Study. Indian Journal of Gastroenterology: Official Journal of the Indian Society of Gastroenterology, 38, 61-68. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Petrick, J.L., This-tle, J.E., Zeleniuch-Jacquotte, A., et al. (2018) Body Mass Index, Diabetes and Intrahepatic Cholangiocarcinoma Risk: The Liver Cancer Pooling Project and Meta-Analysis. The American Journal of Gastroenterology, 113, 1494-1505. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Chun, Y.S. and Javle, M. (2017) Systemic and Adjuvant Thera-pies for Intrahepatic Cholangiocarcinoma. Cancer Control: Journal of the Moffitt Cancer Center, 24, 3. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Rajamäki, K., Taira, A., Katainen, R., et al. (2021) Genetic and Epigenetic Characteristics of Inflammatory Bowel Disease-Associated Colorectal Cancer. Gastroenterology, 161, 592-607. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Shah, S.C. and Itzkowitz, S.H. (2022) Colorectal Can-cer in Inflammatory Bowel Disease: Mechanisms and Management. Gastroenterology, 162, 715-730.e3. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Lo, B., Zhao, M., Vind, I., et al. (2021) The Risk of Extraintesti-nal Cancer in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Population-Based Cohort Stud-ies. Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterolog-ical Association, 19, 1117-1138.e19. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Malham, M., Jakobsen, C., Paerregaard, A., et al. (2019) The Inci-dence of Cancer and Mortality in Paediatric Onset Inflammatory Bowel Disease in Denmark and Finland during a 23-Year Period: A Population-Based Study. Alimentary Pharmacology & Therapeutics, 50, 33-39. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Kouam, C., Warling, O., Van Kemseke, C., et al. (2020) Increased Neo-plastic Risks in Ulcerative Colitis Associated with Primary Sclerosing Cholangitis. Revue Medicale de Liege, 75, 724-730.
|
|
[36]
|
Caruso, R., Lo, B.C. and Núñez, G. (2020) Host-Microbiota Interactions in Inflammatory Bowel Disease. Nature Reviews. Immunology, 20, 411-426. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Trivedi, P.J., Crothers, H., Mytton, J., et al. (2020) Effects of Primary Sclerosing Cholangitis on Risks of Cancer and Death in People with In-flammatory Bowel Disease, Based on Sex, Race, and Age. Gastroenterology, 159, 915-928. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Kubo, S., Takemura, S., Tanaka, S., Shinkawa, H., et al. (2018) Occupational Cholangiocarcinoma Caused by Exposure to 1,2-Dichloropropane and/or Dichloromethane. Annals of Gas-troenterological Surgery, 2, 99-105. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Kato, I. and Kido, C. (1987) Increased Risk of Death in Thorotrast-Exposed Patients during the Late Follow-Up Period. Japanese Journal of Cancer Research: Gann, 78, 1187-1192.
|
|
[40]
|
Kumagai, S., Sobue, T., Makiuchi, T., Kubo, S., Uehara, S., et al. (2016) Relationship between Cumu-lative Exposure to 1,2-Dichloropropane and Incidence Risk of Cholangiocarcinoma among Offset Printing Workers. Oc-cupational and Environmental Medicine, 73, 545-552. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Farioli, A., Straif, K., Brandi, G., et al. (2018) Occupational Exposure to Asbestos and Risk of Cholangiocarcinoma: A Popula-tion-Based Case-Control Study in Four Nordic Countries. Occupational and Environmental Medicine, 75, 191-198. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Squadroni, M., Tondulli, L., Gatta, G., et al. (2017) Cholangio-carcinoma. Critical Reviews in Oncology/Hematology, 116, 11-31. [Google Scholar] [CrossRef] [PubMed]
|